Effect of obesity on pharmacokinetics and drug dosing of remimazolam in patients with obstructive sleep apnoea.

Authors

Xin-Yi Tang, Wen-Wen Ni, Yu-Fei Shi, Jing-Jing Huang, Jing Qin, Ying-Jie Wang, Li-Li Feng, Shuang-Shuang Li, Wen-Xian Li, Yuan Han, Xiao Zhu

Published in

Anaesthesia. Sep 07, 2026. Epub Sep 07, 2026.

Abstract

The pharmacological profile of remimazolam makes it particularly suitable for patients living with obesity. However, how its pharmacokinetics are influenced by varying degrees of obesity and obstructive sleep apnoea severity remains unclear. This study aimed to characterise remimazolam pharmacokinetics in volunteers living with different levels of obesity and obstructive sleep apnoea.
Stepwise escalating infusion of remimazolam was administered until five consecutive modified observer's assessment of alertness and sedation scores of 1 were recorded. Arterial blood samples were collected before infusion, at each infusion rate adjustment step, 5 minutes after each adjustment and several time points post-infusion discontinuation. Drug concentrations were quantified using ultra-high-performance liquid chromatography coupled with triple quadrupole tandem mass spectrometry. A joint population pharmacokinetic model characterising remimazolam and its metabolite CNS7054 was developed.
Forty-four adult volunteers, 30 (68.2%) with obstructive sleep apnoea, were studied. Remimazolam pharmacokinetics were best described by a three-compartment model; a one-compartment model with transit compartment described CNS7054. External validation confirmed robust prediction performance. Clearance of remimazolam was high (1.09 l.min^-1, relative standard error = 4%). Total body weight significantly affected clearance and metabolite volume of distribution. No other covariates, including obstructive sleep apnoea severity, had significant impact. In patients living with class 2/3 obesity, context-sensitive half-time after a 4-h infusion was short (4.02 min). Dosing based on lean/ideal body weight for induction, or adjusted body weight for maintenance, in patients living with class 2/3 obesity yielded pharmacokinetic profiles comparable with those achieved with total body weight dosing in normal weight patients.
Body size significantly alters remimazolam pharmacokinetics and individualised weight-based dosing is essential for populations with obesity. Obstructive sleep apnoea severity does not affect drug disposition; however, its pharmacodynamic effects require further investigation.

PMID:
42703687
Bibliographic data and abstract were imported from PubMed on 07 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.